Monitor for any future conversion to a Schedule 13D, which would signal activist intent. The inclusion of a large warrant component (3.44M shares) means potential dilution if exercised, but the passive filing indicates no current plan to influence control.
EQ drugs
EQ drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 12 $1.32entry
- T+1 · 9d ago −2.27%α −1.91% · $1.29
- T+5 · 3d ago −15.15%α −9.70% · $1.12
- T+6 · todayOpen
- T+20 · in 19d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Adage Capital Management filed an amended Schedule 13G disclosing a 5.93% passive stake in Equillium, representing 3,966,917 shares (including 3,442,514 shares issuable upon exercise of warrants) as of September 30, 2026. This is a routine passive update with no change in investment intent.
Key Financial Metrics
Key Facts
- Adage Capital Management disclosed a 5.93% passive beneficial ownership in Equillium as of September 30, 2026.
- The stake comprises 3,966,917 shares, including 3,442,514 shares issuable upon exercise of warrants.
- The filing is an amendment to a prior Schedule 13G, maintaining passive investor status under Rule 13d-1(b).
- The percentage is based on 63,408,082 shares outstanding as of August 7, 2026, assuming warrant exercise.
Financial Impact
Passive stake of 5.93% with no change in investment intent; no material financial impact.
Risk Factors
- No material risks identified; routine passive stake update.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000919574-26-007564 |
| Document: 0000919574-26-007564-index.html | 0000919574-26-007564 |
| Document: 0000919574-26-007564.txt | 0000919574-26-007564 |
Track record
20 reports on EQ
2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +20.40% at T+60 after the Jun 5, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 20, 20262d ago EFFECT Neutral 4/10 Entry $1.12 Now $1.06 −5.36% settles Nov 23
- Nov 16, 20265d ago SC 13G/A Neutral 3/10 Entry $1.21 to $1.10 Now $1.06 −12.40% ▼ −9.09% −8.79% vs SPY
- Nov 13, 20268d ago SC 13G/A Neutral 2/10 Entry $1.15 to $1.21 Now $1.06 −7.83% ▲ +5.22% +6.23% vs SPY
- Nov 12, 20269d ago S-3 Neutral 4/10 Entry $1.29 to $1.15 Now $1.06 −17.83% ▼ −10.85% −8.94% vs SPY
- Nov 12, 20269d ago 8-K Neutral 5/10 Entry $1.29 to $1.15 Now $1.06 −17.83% ▼ −10.85% −8.94% vs SPY
- Nov 12, 20269d ago SC 13G/A Neutral 2/10 Viewing Entry $1.32 to $1.29 Now $1.06 −19.70% ▼ −2.27% −1.91% vs SPY
- Nov 4, 202617d ago SC 13G/A Neutral 2/10 Entry $1.40 to $1.33 Now $1.06 −24.29% ▼ −5.00% −0.59% vs SPY
- Oct 26, 202626d ago 8-K Bearish 6/10 Entry $1.36 to $1.42 Now $1.06 +22.06% ▼ −4.41% −4.07% vs SPY
- Oct 26, 202626d ago Press Release Neutral 4/10 Entry $1.25 to $1.36 Now $1.06 −15.20% ▲ +8.80% +8.24% vs SPY
- Oct 5, 20266w ago 8-K Neutral 3/10 Entry $1.42 to $1.39 Now $1.06 −25.35% ▼ −2.11% −1.87% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers